MTNB
Matinas Biopharma·AMEX
--
--(--)
--
--(--)
7.57 / 10
Outperform
Fund flow evaluation is the strongest pillar, scoring 7.57/10 with a good rating. Constructive money flow is evident in Small and Extra-large blocks despite negative Medium and Large trends, suggesting institutional nibbling. Although analyst coverage is absent (ana_eval = -1), the positive fund flow and interim CFO appointment provide incremental confidence. Investors focused on momentum may find this aspect supportive, but should still account for technical and fundamental uncertainties.
Fund Flow Rating
Is money flowing into or out of MTNB?
- MTNB holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 7.57/10 (Outperform).
